ArticleThe Journal of biological chemistry2010
Mechanism of regulation of bcl-2 mRNA by nucleolin and A+U-rich element-binding factor 1 (AUF1).
Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review).International journal of molecular medicine · 2023Pooled it
- Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis.Journal of molecular medicine (Berlin, Germany) · 2022Pooled it
- Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma.iScience · 2025Article
- Formulation optimization of lyophilized aptamer-gold nanoparticles: Maintained colloidal stability and cellular uptake.Heliyon · 2024Article
- Galactosylceramide Upregulates the Expression of theCancers · 2024Article
- Review
- The EDC4-XRN1 interaction controls P-body dynamics to link mRNA decapping with decay.The EMBO journal · 2023Article
- SNHG15-Mediated Localization of Nucleolin at the Cell Protrusions Regulates CDH2 mRNA Expression and Cell Invasion.International journal of molecular sciences · 2023Article
- A Unique G-Quadruplex Aptamer: A Novel Approach for Cancer Cell Recognition, Cell Membrane Visualization, and RSV Infection Detection.International journal of molecular sciences · 2023Article
- Cuproptosis-related lncRNAs forecast the prognosis of acute myeloid leukemia.Translational cancer research · 2023Article
- The RGG motif proteins: Interactions, functions, and regulations.Wiley interdisciplinary reviews. RNA · 2023Review
- Anti-nucleolin aptamer AS1411: an advancing therapeutic.Frontiers in molecular biosciences · 2023Review
- RNA binding proteins in MLL-rearranged leukemia.Experimental hematology & oncology · 2022Review
- LINC01296 promotes neuroblastoma tumorigenesis via the NCL-SOX11 regulatory complex.Molecular therapy oncolytics · 2022Article
- PABP prevents the untimely decay of select mRNA populations in human cells.The EMBO journal · 2022Article
- Progress in cancer drug delivery based on AS1411 oriented nanomaterials.Journal of nanobiotechnology · 2022Review
- RNA binding proteins in osteoarthritis.Frontiers in cell and developmental biology · 2022Review
- Nucleolin Rescues TDP-43 Toxicity in Yeast and Human Cell Models.Frontiers in cellular neuroscience · 2021Article
- Nucleolin Promotes Cisplatin Resistance in Cervical Cancer by the YB1-MDR1 Pathway.Journal of oncology · 2021Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The antiapoptotic Bcl-2 protein is overexpressed in a variety of cancers, particularly leukemias. In some cell types this is the result of enhanced stability of bcl-2 mRNA, which is controlled by elements in its 3'-untranslated region. Nucleolin is one of the proteins that binds to bcl-2 mRNA, thereby increasing its half-life. Here, we examined the site on the bcl-2 3'-untranslated region that is bound by nucleolin as well as the protein binding domains important for bcl-2 mRNA recognition. RNase footprinting and RNA fragment binding assays demonstrated that nucleolin binds to a 40-nucleotide region at the 5' end of the 136-nucleotide bcl-2 AU-rich element (ARE(bcl-2)). The first two RNA binding domains of nucleolin were sufficient for high affinity binding to ARE(bcl-2). In RNA decay assays, ARE(bcl-2) transcripts were protected from exosomal decay by the addition of nucleolin. AUF1 has been shown to recruit the exosome to mRNAs. When MV-4-11 cell extracts were immunodepleted of AUF1, the rate of decay of ARE(bcl-2) transcripts was reduced, indicating that nucleolin and AUF1 have opposing roles in bcl-2 mRNA turnover. When the function of nucleolin in MV-4-11 cells was impaired by treatment with the nucleolin-targeting aptamer AS1411, association of AUF1 with bcl-2 mRNA was increased. This suggests that the degradation of bcl-2 mRNA induced by AS1411 results from both interference with nucleolin protection of bcl-2 mRNA and recruitment of the exosome by AUF1. Based on our findings, we propose a model that illustrates the opposing roles of nucleolin and AUF1 in regulating bcl-2 mRNA stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.